Ignite Creation Date:
2025-12-25 @ 1:31 AM
Ignite Modification Date:
2025-12-27 @ 11:45 PM
Study NCT ID:
NCT05604794
Status:
COMPLETED
Last Update Posted:
2024-03-20
First Post:
2022-10-12
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Retrospective Effectiveness Trial of Ketamine-Assisted Psychotherapy in Adult Patients Coping With Mental Health
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003863', 'term': 'Depression'}, {'id': 'D001008', 'term': 'Anxiety Disorders'}, {'id': 'D013313', 'term': 'Stress Disorders, Post-Traumatic'}, {'id': 'D000092862', 'term': 'Psychological Well-Being'}], 'ancestors': [{'id': 'D001526', 'term': 'Behavioral Symptoms'}, {'id': 'D001519', 'term': 'Behavior'}, {'id': 'D001523', 'term': 'Mental Disorders'}, {'id': 'D040921', 'term': 'Stress Disorders, Traumatic'}, {'id': 'D000068099', 'term': 'Trauma and Stressor Related Disorders'}, {'id': 'D010549', 'term': 'Personal Satisfaction'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'chris.lo@utoronto.ca', 'phone': '65 6709 3003', 'title': 'Dr Chris Lo', 'phoneExt': '203', 'organization': 'University of Toronto'}, 'certainAgreement': {'otherDetails': 'The disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results.', 'restrictionType': 'OTHER', 'piSponsorEmployee': False, 'restrictiveAgreement': True}, 'limitationsAndCaveats': {'description': 'Based on feedback from the peer review process, this study should be considered a cohort study rather than a trial. The high attrition rate may limit validity of results.'}}, 'adverseEventsModule': {'timeFrame': '6 months', 'eventGroups': [{'id': 'EG000', 'title': 'Clients', 'description': 'Adult patients coping with symptoms of depression, anxiety, and post traumatic stress\n\nKetamine-Assisted Psychotherapy (KAP): KAP consisting of 4-6 guided ketamine sessions with psychotherapy-only visits after dose 1 and 2 and then after every 2 subsequent doses.', 'otherNumAtRisk': 1806, 'deathsNumAtRisk': 1806, 'otherNumAffected': 0, 'seriousNumAtRisk': 1806, 'deathsNumAffected': 0, 'seriousNumAffected': 0}], 'frequencyThreshold': '0'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': '9-item Patient Health Questionnaire (PHQ-9)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '315', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Clients', 'description': 'Adult patients coping with symptoms of depression, anxiety, and post traumatic stress\n\nKetamine-Assisted Psychotherapy (KAP): KAP consisting of 4-6 guided ketamine sessions with psychotherapy-only visits after dose 1 and 2 and then after every 2 subsequent doses.'}], 'classes': [{'categories': [{'measurements': [{'value': '-3.23', 'groupId': 'OG000', 'lowerLimit': '-3.57', 'upperLimit': '-2.90'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Change from 3 months compared to baseline', 'description': 'Self-reported measure of depression, ranging from 0-27. Higher scores are worse.', 'unitOfMeasure': 'units on a scale', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Number analysed after attrition.'}, {'type': 'PRIMARY', 'title': '7-item Generalized Anxiety Disorder Measure (GAD-7)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '305', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Clients', 'description': 'Adult patients coping with symptoms of depression, anxiety, and post traumatic stress\n\nKetamine-Assisted Psychotherapy (KAP): KAP consisting of 4-6 guided ketamine sessions with psychotherapy-only visits after dose 1 and 2 and then after every 2 subsequent doses.'}], 'classes': [{'categories': [{'measurements': [{'value': '-4.80', 'groupId': 'OG000', 'lowerLimit': '-5.17', 'upperLimit': '-4.44'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Change from 3 months compared to baseline', 'description': 'Self-reported measure of anxiety, ranging from 0-21. Higher scores are worse.', 'unitOfMeasure': 'units on a scale', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Number analysed after attrition.'}, {'type': 'PRIMARY', 'title': '6-item PTSD Checklist (PCL-6)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '299', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Clients', 'description': 'Adult patients coping with symptoms of depression, anxiety, and post traumatic stress\n\nKetamine-Assisted Psychotherapy (KAP): KAP consisting of 4-6 guided ketamine sessions with psychotherapy-only visits after dose 1 and 2 and then after every 2 subsequent doses.'}], 'classes': [{'categories': [{'measurements': [{'value': '-4.24', 'groupId': 'OG000', 'lowerLimit': '-4.60', 'upperLimit': '-3.87'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Change from 3 months compared to baseline', 'description': 'Self-reported measure of post traumatic stress, ranging from 6-30. Higher scores are worse.', 'unitOfMeasure': 'units on a scale', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Number analysed after attrition.'}, {'type': 'SECONDARY', 'title': '9-item Patient Health Questionnaire (PHQ-9)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '330', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Clients', 'description': 'Adult patients coping with symptoms of depression, anxiety, and post traumatic stress\n\nKetamine-Assisted Psychotherapy (KAP): KAP consisting of 4-6 guided ketamine sessions with psychotherapy-only visits after dose 1 and 2 and then after every 2 subsequent doses.'}], 'classes': [{'categories': [{'measurements': [{'value': '-3.23', 'groupId': 'OG000', 'lowerLimit': '-3.57', 'upperLimit': '-2.90'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Change from 1 month compared to baseline', 'description': 'Self-reported measure of depression, ranging from 0-27.', 'unitOfMeasure': 'units on a scale', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': '9-item Patient Health Questionnaire (PHQ-9)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '92', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Clients', 'description': 'Adult patients coping with symptoms of depression, anxiety, and post traumatic stress\n\nKetamine-Assisted Psychotherapy (KAP): KAP consisting of 4-6 guided ketamine sessions with psychotherapy-only visits after dose 1 and 2 and then after every 2 subsequent doses.'}], 'classes': [{'categories': [{'measurements': [{'value': '-4.74', 'groupId': 'OG000', 'lowerLimit': '-5.68', 'upperLimit': '-3.80'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Change from 6 months compared to baseline', 'description': 'Self-reported measure of depression, ranging from 0-27.', 'unitOfMeasure': 'units on a scale', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': '7-item Generalized Anxiety Disorder Measure (GAD-7)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '333', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Clients', 'description': 'Adult patients coping with symptoms of depression, anxiety, and post traumatic stress\n\nKetamine-Assisted Psychotherapy (KAP): KAP consisting of 4-6 guided ketamine sessions with psychotherapy-only visits after dose 1 and 2 and then after every 2 subsequent doses.'}], 'classes': [{'categories': [{'measurements': [{'value': '-2.65', 'groupId': 'OG000', 'lowerLimit': '-2.95', 'upperLimit': '-2.34'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Change from 1 month compared to baseline', 'description': 'Self-reported measure of anxiety, ranging from 0-21.', 'unitOfMeasure': 'units on a scale', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': '7-item Generalized Anxiety Disorder Measure (GAD-7)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '72', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Clients', 'description': 'Adult patients coping with symptoms of depression, anxiety, and post traumatic stress\n\nKetamine-Assisted Psychotherapy (KAP): KAP consisting of 4-6 guided ketamine sessions with psychotherapy-only visits after dose 1 and 2 and then after every 2 subsequent doses.'}], 'classes': [{'categories': [{'measurements': [{'value': '-4.10', 'groupId': 'OG000', 'lowerLimit': '-5.02', 'upperLimit': '-3.18'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Change from 6 months compared to baseline', 'description': 'Self-reported measure of anxiety, ranging from 0-21.', 'unitOfMeasure': 'units on a scale', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': '6-item PTSD Checklist (PCL-6)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '327', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Clients', 'description': 'Adult patients coping with symptoms of depression, anxiety, and post traumatic stress\n\nKetamine-Assisted Psychotherapy (KAP): KAP consisting of 4-6 guided ketamine sessions with psychotherapy-only visits after dose 1 and 2 and then after every 2 subsequent doses.'}], 'classes': [{'categories': [{'measurements': [{'value': '-2.14', 'groupId': 'OG000', 'lowerLimit': '-2.44', 'upperLimit': '-1.83'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Change from 1 month compared to baseline', 'description': 'Self-reported measure of post traumatic stress, ranging from 6-30.', 'unitOfMeasure': 'units on a scale', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': '6-item PTSD Checklist (PCL-6)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '69', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Clients', 'description': 'Adult patients coping with symptoms of depression, anxiety, and post traumatic stress\n\nKetamine-Assisted Psychotherapy (KAP): KAP consisting of 4-6 guided ketamine sessions with psychotherapy-only visits after dose 1 and 2 and then after every 2 subsequent doses.'}], 'classes': [{'categories': [{'measurements': [{'value': '-3.44', 'groupId': 'OG000', 'lowerLimit': '-4.38', 'upperLimit': '-2.50'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Change from 6 months compared to baseline', 'description': 'Self-reported measure of post traumatic stress, ranging from 6-30.', 'unitOfMeasure': 'units on a scale', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Clients', 'description': 'Adult patients coping with symptoms of depression, anxiety, and post traumatic stress\n\nKetamine-Assisted Psychotherapy (KAP): KAP consisting of 4-6 guided ketamine sessions with psychotherapy-only visits after dose 1 and 2 and then after every 2 subsequent doses.'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '1806'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '94'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '1712'}]}]}]}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '1806', 'groupId': 'BG000'}]}], 'groups': [{'id': 'BG000', 'title': 'Clients', 'description': 'Adult patients coping with symptoms of depression, anxiety, and post traumatic stress\n\nKetamine-Assisted Psychotherapy (KAP): KAP consisting of 4-6 guided ketamine sessions with psychotherapy-only visits after dose 1 and 2 and then after every 2 subsequent doses.'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '42', 'spread': '12', 'groupId': 'BG000'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex/Gender, Customized', 'classes': [{'title': 'Gender', 'categories': [{'title': 'Female', 'measurements': [{'value': '948', 'groupId': 'BG000'}]}, {'title': 'Male', 'measurements': [{'value': '850', 'groupId': 'BG000'}]}, {'title': 'Non-binary', 'measurements': [{'value': '8', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race/Ethnicity, Customized', 'classes': [{'title': 'Race/Ethnicity', 'categories': [{'title': 'White', 'measurements': [{'value': '1309', 'groupId': 'BG000'}]}, {'title': 'Other Groups', 'measurements': [{'value': '441', 'groupId': 'BG000'}]}, {'title': 'Missing', 'measurements': [{'value': '56', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Region of Enrollment', 'classes': [{'title': 'North America', 'categories': [{'measurements': [{'value': '1806', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}]}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2022-10-14', 'size': 215269, 'label': 'Study Protocol and Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'Prot_SAP_001.pdf', 'typeAbbrev': 'Prot_SAP', 'uploadDate': '2023-04-19T23:09', 'hasProtocol': True}, {'date': '2021-06-01', 'size': 288232, 'label': 'Informed Consent Form', 'hasIcf': True, 'hasSap': False, 'filename': 'ICF_000.pdf', 'typeAbbrev': 'ICF', 'uploadDate': '2022-09-29T04:05', 'hasProtocol': False}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE4'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 1806}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2020-03-13', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2024-02', 'completionDateStruct': {'date': '2022-06-16', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-02-22', 'studyFirstSubmitDate': '2022-10-12', 'resultsFirstSubmitDate': '2023-04-14', 'studyFirstSubmitQcDate': '2022-10-30', 'lastUpdatePostDateStruct': {'date': '2024-03-20', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2023-04-19', 'studyFirstPostDateStruct': {'date': '2022-11-03', 'type': 'ACTUAL'}, 'resultsFirstPostDateStruct': {'date': '2023-05-12', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2022-06-16', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': '9-item Patient Health Questionnaire (PHQ-9)', 'timeFrame': 'Change from 3 months compared to baseline', 'description': 'Self-reported measure of depression, ranging from 0-27. Higher scores are worse.'}, {'measure': '7-item Generalized Anxiety Disorder Measure (GAD-7)', 'timeFrame': 'Change from 3 months compared to baseline', 'description': 'Self-reported measure of anxiety, ranging from 0-21. Higher scores are worse.'}, {'measure': '6-item PTSD Checklist (PCL-6)', 'timeFrame': 'Change from 3 months compared to baseline', 'description': 'Self-reported measure of post traumatic stress, ranging from 6-30. Higher scores are worse.'}], 'secondaryOutcomes': [{'measure': '9-item Patient Health Questionnaire (PHQ-9)', 'timeFrame': 'Change from 1 month compared to baseline', 'description': 'Self-reported measure of depression, ranging from 0-27.'}, {'measure': '9-item Patient Health Questionnaire (PHQ-9)', 'timeFrame': 'Change from 6 months compared to baseline', 'description': 'Self-reported measure of depression, ranging from 0-27.'}, {'measure': '7-item Generalized Anxiety Disorder Measure (GAD-7)', 'timeFrame': 'Change from 1 month compared to baseline', 'description': 'Self-reported measure of anxiety, ranging from 0-21.'}, {'measure': '7-item Generalized Anxiety Disorder Measure (GAD-7)', 'timeFrame': 'Change from 6 months compared to baseline', 'description': 'Self-reported measure of anxiety, ranging from 0-21.'}, {'measure': '6-item PTSD Checklist (PCL-6)', 'timeFrame': 'Change from 1 month compared to baseline', 'description': 'Self-reported measure of post traumatic stress, ranging from 6-30.'}, {'measure': '6-item PTSD Checklist (PCL-6)', 'timeFrame': 'Change from 6 months compared to baseline', 'description': 'Self-reported measure of post traumatic stress, ranging from 6-30.'}]}, 'oversightModule': {'isUsExport': False, 'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['ketamine', 'psychotherapy', 'mental health'], 'conditions': ['Depression', 'Anxiety', 'Post Traumatic Stress Disorder']}, 'descriptionModule': {'briefSummary': 'Ketamine-Assisted Psychotherapy (KAP) is a relatively new approach for the treatment of mental health issues, which involves the combination of ketamine, a dissociative anaesthetic with psychedelic properties, and psychotherapy to promote emotional wellbeing. In this study, we investigated the effectiveness of KAP in adult patients coping with mental health. We predicted that clients would experience lasting reductions in psychological distress over time, such as depression, anxiety, and post traumatic stress, that would be detectable up to 6 months after treatment. The results of this study may provide evidence of sustained real-world effects of Ketamine-Assisted Psychotherapy, of interest to patients, clinicians, researchers, and policymakers.', 'detailedDescription': 'Background: Ketamine-Assisted Psychotherapy (KAP) has shown positive effects within clinical trial settings and over short-term follow-ups, but sustained effects in real-world treatment settings remain unclear. In this study, we investigated the effectiveness of KAP in adult patients coping with mental health issues. We hypothesized that there would be significant reductions in psychological distress over time.\n\nObjective: To examine treatment effects at 1, 3, and 6 months relative to baseline on depression, anxiety, and post traumatic stress outcomes.\n\nDesign: A retrospective intervention-only effectiveness trial.\n\nSetting: KAP was administered across 11 Field Trip Health clinics in North America. Intervention: KAP consisting of 4-6 guided ketamine sessions with psychotherapy-only visits after dose 1 and 2 and then after every 2 subsequent doses.\n\nOutcomes: Self-reported measures of symptoms of depression, anxiety, and post traumatic stress at 1, 3, and 6 months.\n\nStatistical Analysis: Analyses were by intention to treat. Main analysis was a mixed linear model or growth curve model to estimate change over time per outcome, yielding estimates of mean changes at each endpoint relative to baseline. Secondary analyses included evaluating case reductions (identified by cut-off values) and minimal clinically important differences (MCIDs) at each endpoint relative to baseline.\n\nSignificance: This study may provide evidence of sustained real-world effects of Ketamine-Assisted Psychotherapy, of interest to patients, clinicians, researchers, and policymakers.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '19 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Written informed consent\n* Over the age of 18\n* Should be psychologically and medically cleared by a psychiatrist, family physician, or treatment team\n* Diagnosed with Major Depressive Disorder (MDD), Bipolar Depression, Generalized Anxiety Disorder, Obsessive Compulsive Disorder (OCD), and Eating Disorder by a licensed healthcare practitioner (including Field Trip Consultants)\n* A significant history of trauma and/or formal diagnosis of PTSD as per the Diagnostic and Statistical Manual of Mental Disorders 5 (DSM 5)\n* Individuals who have received Electroconvulsive Therapy (ECT) or other neuromodulatory treatments like Transcranial Magnetic Stimulation (TMS)\n* Individuals reporting suicidal ideation may be included, as suicidal ideation is a symptom of a Major Depressive Episode (MDE)\n\nExclusion Criteria:\n\n* Individuals who are unable to consent to the treatment\n* Pregnant women and nursing mothers\n\n --Note that Post Partum Depression (PPD) can be considered on a case-by-case basis in consultation with the National Medical Director.\n* There is a relative (not absolute) contraindication for individuals with a Body Mass Index (BMI) of above 35. These clients must be given thorough consideration by the medical team.\n* Any individual who has met DSM 5 criteria for a Substance Use Disorder in the past 3 months.\n\n * Note that patients with alcohol, opioid, benzodiazepine, cocaine, and amphetamine use disorders need to go through detox (for alcohol/benzodiazepines) and be sober for 4 weeks.\n * Note that mild active alcohol, cocaine, and cannabis use can be considered on a case-by-case basis at the comfort level of the treatment team if the client has demonstrated abstaining or significant reduction of use prior to starting treatment.\n* Daily use of moderate to high doses of benzodiazepines\n* Individuals who are experiencing psychotic symptoms as part of an MDE (mood congruent/ mood incongruent)\n* Psychosis: Schizophrenia, Schizoaffective disorder, Bipolar 1 with psychotic features during mania\n* Active Mania: Bipolar 1 (chronic non-disruptive hypomania is an exception at the discretion of the consultant)\n* Borderline Personality Disorder\n* Uncontrolled medical disorders\n* Physical conditions with negative interaction with ketamine (e.g., metabolic blood disorder)\n* Individuals with symptomatic acute brain injury within 90 days of serious injury\n* Individuals diagnosed with moderate to severe sleep apnea\n* Individuals who are unable to identify a person or service to assure their safe transport to home post treatment'}, 'identificationModule': {'nctId': 'NCT05604794', 'briefTitle': 'A Retrospective Effectiveness Trial of Ketamine-Assisted Psychotherapy in Adult Patients Coping With Mental Health', 'organization': {'class': 'INDUSTRY', 'fullName': 'Field Trip Health'}, 'officialTitle': 'Retrospective Review of Ketamine Assisted Psychotherapy Program on Mental Health at Field Trip Health Centres in North America', 'orgStudyIdInfo': {'id': '2022-3067-11240-5'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Clients', 'description': 'Adult patients coping with symptoms of depression, anxiety, and post traumatic stress', 'interventionNames': ['Combination Product: Ketamine-Assisted Psychotherapy (KAP)']}], 'interventions': [{'name': 'Ketamine-Assisted Psychotherapy (KAP)', 'type': 'COMBINATION_PRODUCT', 'description': 'KAP consisting of 4-6 guided ketamine sessions with psychotherapy-only visits after dose 1 and 2 and then after every 2 subsequent doses.', 'armGroupLabels': ['Clients']}]}, 'contactsLocationsModule': {'locations': [{'zip': '90404', 'city': 'Los Angeles', 'state': 'California', 'country': 'United States', 'facility': 'LA Centre', 'geoPoint': {'lat': 34.05223, 'lon': -118.24368}}, {'zip': '92037', 'city': 'San Diego', 'state': 'California', 'country': 'United States', 'facility': 'San Diego Centre', 'geoPoint': {'lat': 32.71571, 'lon': -117.16472}}, {'zip': '20005', 'city': 'Washington D.C.', 'state': 'District of Columbia', 'country': 'United States', 'facility': 'Washington DC Centre', 'geoPoint': {'lat': 38.89511, 'lon': -77.03637}}, {'zip': '30316', 'city': 'Atlanta', 'state': 'Georgia', 'country': 'United States', 'facility': 'Atlanta Centre', 'geoPoint': {'lat': 33.749, 'lon': -84.38798}}, {'zip': '60654', 'city': 'Chicago', 'state': 'Illinois', 'country': 'United States', 'facility': 'Chicago Centre', 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}}, {'zip': '10010', 'city': 'New York', 'state': 'New York', 'country': 'United States', 'facility': 'NYC Centre', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '77027', 'city': 'Houston', 'state': 'Texas', 'country': 'United States', 'facility': 'Houston Centre', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'zip': '98109', 'city': 'Seattle', 'state': 'Washington', 'country': 'United States', 'facility': 'Seattle Centre', 'geoPoint': {'lat': 47.60621, 'lon': -122.33207}}, {'zip': 'V6J 5B3', 'city': 'Vancouver', 'state': 'British Columbia', 'country': 'Canada', 'facility': 'Vancouver Centre', 'geoPoint': {'lat': 49.24966, 'lon': -123.11934}}, {'zip': 'E3B 7E6', 'city': 'Fredericton', 'state': 'New Brunswick', 'country': 'Canada', 'facility': 'Fredericton Centre', 'geoPoint': {'lat': 45.94541, 'lon': -66.66558}}, {'zip': 'M5V 2C3', 'city': 'Toronto', 'state': 'Ontario', 'country': 'Canada', 'facility': 'Field Trip Health, Toronto Centre', 'geoPoint': {'lat': 43.70643, 'lon': -79.39864}}], 'overallOfficials': [{'name': 'Ryan Yermus, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Field Trip Health'}, {'name': 'Chris Lo, PhD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'University of Toronto'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Field Trip Health', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}